Citius Oncology (NASDAQ:CTOR) Earns Buy Rating from Analysts at Maxim Group

Equities researchers at Maxim Group began coverage on shares of Citius Oncology (NASDAQ:CTOR) in a report issued on Wednesday,Briefing.com Automated Import reports. The firm set a “buy” rating and a $3.00 price target on the stock. Maxim Group’s target price suggests a potential upside of 201.24% from the stock’s previous close.

Citius Oncology Trading Up 17.2 %

CTOR stock opened at $1.00 on Wednesday. Citius Oncology has a 1-year low of $0.85 and a 1-year high of $49.00. The business’s 50 day simple moving average is $1.21.

Citius Oncology Company Profile

TenX Keane Acquisition Corp. is a blank check company. It formed for the purpose to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. TenX Keane Acquisition Corp. is based in New York.